Medicare Enrolled
Dr. John Renshaw, M.D.
Hematology & Oncology · San Antonio, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Renshaw from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Renshaw? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Renshaw
Dr. John Renshaw is a hematology & oncology in San Antonio, TX, with 18 years in practice. Based on federal Medicare data, Dr. Renshaw performed 54,860 Medicare services across 2,820 unique beneficiaries.
Between the years covered by Open Payments, Dr. Renshaw received a total of $321,716 from 60 pharmaceutical and/or device companies across 458 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Renshaw is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice▲ Top 17% volume in TX$ $321,716 industry payments
Medicare Practice Summary
Medicare Utilization ↗54,860
Medicare services
Top 17% in TX for hematology & oncology
2,820
Unique beneficiaries
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~3,048 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Darbepoetin injection (Aranesp) for anemia | 20,800 | $2 | $20 |
| Anti-nausea injection (fosaprepitant) | 10,350 | $0 | $5 |
| Contrast dye for imaging (iodine-based) | 7,325 | $0 | $3 |
| Immune globulin infusion (Octagam) | 5,030 | $34 | $234 |
| Dexamethasone injection (steroid) | 1,282 | $0 | $1 |
| Blood draw (venipuncture) | 974 | $8 | $20 |
| Anti-nausea injection (Aloxi/palonosetron) | 930 | $1 | $114 |
| Complete blood count (CBC) with differential | 822 | $8 | $36 |
| Injection, granisetron hydrochloride, 100 mcg | 670 | $0 | $24 |
| Office visit, established patient (20-29 min) | 566 | $62 | $250 |
| Injection, leucovorin calcium, per 50 mg | 563 | $3 | $25 |
| Comprehensive metabolic blood panel | 479 | $10 | $64 |
| Injection, fluorouracil, 500 mg | 457 | $2 | $13 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 358 | $21 | $157 |
| Flow cytometry, additional marker | 332 | $18 | $180 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 266 | $3 | $373 |
| Administration of chemotherapy into vein, 1 hour or less | 250 | $98 | $707 |
| Office visit, established patient (30-39 min) | 237 | $90 | $368 |
| Measurement of immunoglobulin light chains | 204 | $17 | $60 |
| Hospital follow-up visit, moderate complexity | 165 | $60 | $247 |
| Lactate dehydrogenase (enzyme) level | 143 | $6 | $31 |
| Microscopic examination for white blood cells with manual cell count | 143 | $4 | $22 |
| Complete blood count (CBC), automated | 142 | $6 | $34 |
| Injection of additional new drug or substance into vein | 142 | $11 | $108 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 134 | $47 | $313 |
| Reticulated (young) platelet measurement | 131 | $35 | $143 |
| Ferritin level test (iron stores) | 130 | $13 | $60 |
| Injection, diphenhydramine hcl, up to 50 mg | 126 | $1 | $7 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 123 | $15 | $100 |
| Drug injection, under skin or into muscle | 123 | $11 | $96 |
| Injection, zoledronic acid, 1 mg | 115 | $6 | $431 |
| Hospital follow-up visit, low complexity | 106 | $38 | $135 |
| Administration of chemotherapy into vein, each additional hour | 100 | $21 | $161 |
| Immunoglobulin level test | 87 | $9 | $56 |
| Administration of additional new drug or substance into vein, 1 hour or less | 87 | $48 | $344 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 81 | $55 | $211 |
| Basic metabolic blood panel | 77 | $8 | $49 |
| Office visit, established patient, complex (40-54 min) | 68 | $129 | $496 |
| Ct scan of chest with contrast | 66 | $47 | $821 |
| CT scan of abdomen and pelvis with contrast | 61 | $172 | $1,067 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 47 | $15 | $94 |
| Administration of additional new drug or substance into vein using push technique | 46 | $42 | $289 |
| Carcinoembryonic antigen (cea) protein level | 41 | $18 | $99 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 41 | $122 | $500 |
| Prothrombin time test (blood clotting) | 37 | $4 | $30 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 36 | $1 | $19 |
| Hospital follow-up visit, high complexity | 33 | $89 | $357 |
| Iron level test | 30 | $6 | $27 |
| Iron binding capacity test | 30 | $8 | $35 |
| Protein measurement, serum | 29 | $11 | $99 |
| Irrigation of implanted venous access drug delivery device | 26 | $18 | $114 |
| Sed rate test (inflammation marker) | 24 | $3 | $36 |
| Infusion, normal saline solution , 1000 cc | 22 | $2 | $19 |
| New patient office visit (45-59 min) | 19 | $122 | $565 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 19 | $90 | $657 |
| Vitamin B-12 level test | 18 | $15 | $76 |
| CT scan of chest, without contrast | 17 | $28 | $686 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 16 | $272 | $2,762 |
| Ct scan of abdomen and pelvis without contrast | 15 | $70 | $560 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 15 | $1,109 | $4,802 |
| New patient office visit (30-44 min) | 14 | $74 | $372 |
| Initial hospital admission, moderate complexity | 14 | $100 | $470 |
| Flow cytometry technique for dna or cell analysis, first marker | 13 | $56 | $298 |
| Infusion into a vein for hydration, 31-60 minutes | 13 | $25 | $256 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
10.6% high complexity
79.8% medium
9.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$321,716
Total received (2018-2024)
Avg $45,959/year across 7 years
Top 2% in TX for hematology & oncology
60
Companies
458
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$294,754 (91.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$20,906 (6.5%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,056 (1.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$104,004
2023$141,293
2022$27,162
2021$15,417
2020$14,854
2019$13,212
2018$5,775
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
BeiGene USA, Inc.
$128,529
Karyopharm Therapeutics Inc.
$47,009
Amgen Inc.
$33,299
ABBVIE INC.
$32,885
AstraZeneca Pharmaceuticals LP
$28,701
GlaxoSmithKline, LLC.
$16,188
Genentech USA, Inc.
$8,584
Jazz Pharmaceuticals Inc.
$7,969
AbbVie Inc.
$7,239
Seagen Inc.
$2,600
Novocure Inc.
$1,272
Aadi Bioscience, Inc.
$1,000
GENZYME CORPORATION
$638
BeiGene, Ltd.
$525
Takeda Pharmaceuticals U.S.A., Inc.
$478
Novartis Pharmaceuticals Corporation
$431
E.R. Squibb & Sons, L.L.C.
$428
Janssen Biotech, Inc.
$266
Exelixis Inc.
$262
Incyte Corporation
$215
Seattle Genetics, Inc.
$192
Bayer HealthCare Pharmaceuticals Inc.
$182
Astellas Pharma US Inc
$156
AbbVie, Inc.
$153
Adaptive Biotechnologies Corporation
$146
Ipsen Biopharmaceuticals, Inc
$140
EMD Serono, Inc.
$140
TESARO, Inc.
$129
Genmab U.S., Inc.
$125
Bayer Healthcare Pharmaceuticals Inc.
$125
ImmunoGen, Inc.
$125
G1 Therapeutics, Inc.
$125
PFIZER INC.
$123
Agios Pharmaceuticals, Inc.
$122
Merck Sharp & Dohme Corporation
$113
Celgene Corporation
$112
PTC Therapeutics, Inc.
$107
Janssen Pharmaceuticals, Inc
$97
Verastem, Inc.
$89
Lilly USA, LLC
$85
Daiichi Sankyo Inc.
$62
JAZZ PHARMACEUTICALS INC.
$57
Puma Biotechnology, Inc.
$53
Regeneron Healthcare Solutions, Inc.
$47
Alexion Pharmaceuticals, Inc.
$47
Kite Pharma, Inc.
$46
EISAI INC.
$39
Rigel Pharmaceuticals, Inc.
$38
Helsinn Therapeutics (U.S.), Inc.
$32
Apellis Pharmaceuticals, Inc.
$30
Gilead Sciences, Inc.
$27
TerSera Therapeutics LLC
$22
Boehringer Ingelheim Pharmaceuticals, Inc.
$19
PORTOLA PHARMACEUTICALS, INC.
$16
Pharmacyclics LLC, An AbbVie Company
$15
Medtronic USA, Inc.
$15
Clovis Oncology, Inc.
$14
Taiho Oncology, Inc.
$13
Dendreon Pharmaceuticals LLC
$13
Secura Bio, Inc.
$9
Top 3 companies account for 64.9% of total payments
Associated products mentioned in payments ›
ADCETRIS · AKYNZEO · ANDEXXA · Abraxane · Avastin · BOSULIF · BRUKINSA · Balversa · Bavencio · Blincyto · CABLIVI · CALQUENCE · COSELA · CYRAMZA · Cabometyx · Columvi · Copiktra · DARZALEX · ELITEK · EMEND · EMPLICITI · ERLEADA · EXKIVITY · Elahere · Empaveli · Enhertu · Epkinly · FARYDAK · FRUZAQLA · FYARRO · GAZYVA · GILOTRIF · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · Imbruvica · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LYNPARZA · Lenvima · Lonsurf · Lunsumio · Lupron Depot · MEKINIST · MVASI · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OJJAARA · OPDIVO · OSTEOCOOL RF ABLATION · Onivyde · PIQRAY · PROMACTA · PROVENGE · RETEVMO · RYDAPT · Revlimid · Rubraca · SANDOSTATIN · SARCLISA · SOMATULINE DEPOT · SPRYCEL · Stivarga · TAGRISSO · TASIGNA · TIBSOVO · TIVDAK · Tavalisse · ULTOMIRIS · VENCLEXTA · VOTRIENT · VYXEOS · Vectibix · Venclexta · Vitrakvi · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · Xofigo · Yescarta · ZEJULA · ZOLADEX · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (92%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 2% for hematology & oncology in TX.
Equivalent to $586 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
56
Per 100K population
2.7
County median income
$70,571
Nearest hospital
SAN ANTONIO BEHAVIORAL HEALTHCARE HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Renshaw is a mixed practice specialist, with above-average Medicare volume (top 17% in TX), and high industry engagement (speaking/promotional, top 2%), with 18 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Renshaw experienced with darbepoetin injection (aranesp) for anemia?
Based on Medicare claims data, Dr. Renshaw performed 20,800 darbepoetin injection (aranesp) for anemia services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Renshaw receive payments from pharmaceutical companies?
Yes. Dr. Renshaw received a total of $321,716 from 60 companies across 458 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Renshaw's costs compare to other hematology & oncologys in San Antonio?
Dr. Renshaw's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Renshaw) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in San Antonio
Browse hematology & oncologys in San Antonio ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in TX
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in TX
Which TX hematology & oncologys receive the most from drug and device companies.
By company
BeiGene USA, Inc. Payments to Doctors
See all physicians who received payments from BeiGene USA, Inc..
By company
Karyopharm Therapeutics Inc. Payments to Doctors
See all physicians who received payments from Karyopharm Therapeutics Inc..
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology